{ "version": "2.2", "instance": { "btai-20230930x10q.htm": { "nsprefix": "btai", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "dts": { "schema": { "local": [ "btai-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] }, "calculationLink": { "local": [ "btai-20230930_cal.xml" ] }, "definitionLink": { "local": [ "btai-20230930_def.xml" ] }, "labelLink": { "local": [ "btai-20230930_lab.xml" ] }, "presentationLink": { "local": [ "btai-20230930_pre.xml" ] }, "inline": { "local": [ "btai-20230930x10q.htm" ] } }, "keyStandard": 267, "keyCustom": 44, "axisStandard": 22, "axisCustom": 0, "memberStandard": 30, "memberCustom": 28, "hidden": { "total": 15, "http://fasb.org/us-gaap/2022": 10, "http://xbrl.sec.gov/dei/2022": 5 }, "contextCount": 200, "entityCount": 1, "segmentCount": 58, "elementCount": 480, "unitCount": 7, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 30, "http://fasb.org/us-gaap/2022": 612 }, "report": { "R1": { "role": "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets", "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_9_30_2023_YaZVjLTSkU6Y_nWVYzVsmg", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_YaZVjLTSkU6Y_nWVYzVsmg", "name": "us-gaap:ReceivablesNetCurrent", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "unique": true } }, "R3": { "role": "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_9_30_2023_YaZVjLTSkU6Y_nWVYzVsmg", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_6qPEhVosL02ww44K4nRFiQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_YaZVjLTSkU6Y_nWVYzVsmg", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_6qPEhVosL02ww44K4nRFiQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations", "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_o5fnxzMCYk-cLU56wWtHRQ", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_o5fnxzMCYk-cLU56wWtHRQ", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity", "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__-fG_eyKQket-OBucSzFvA", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nJa2ayONrUWD2tzqJSYUeQ", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "unique": true } }, "R6": { "role": "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureNatureOfBusiness", "longName": "10101 - Disclosure - Nature of the Business", "shortName": "Nature of the Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation", "longName": "10201 - Disclosure - Basis of Presentation", "shortName": "Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "10301 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureRestructuring", "longName": "10401 - Disclosure - Restructuring", "shortName": "Restructuring", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureInventory", "longName": "10501 - Disclosure - Inventory", "shortName": "Inventory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet", "longName": "10601 - Disclosure - Property and Equipment, Net", "shortName": "Property and Equipment, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses", "longName": "10701 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc", "longName": "10801 - Disclosure - Transactions with BioXcel LLC", "shortName": "Transactions with BioXcel LLC", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities", "longName": "10901 - Disclosure - Debt and Credit Facilities", "shortName": "Debt and Credit Facilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstruments", "longName": "11001 - Disclosure - Derivative Financial Instruments", "shortName": "Derivative Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities", "longName": "11101 - Disclosure - Common Stock Financing Activities", "shortName": "Common Stock Financing Activities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "btai:FinancingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "btai:FinancingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation", "longName": "11201 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureLeases", "longName": "11301 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements", "longName": "11401 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare", "longName": "11501 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies", "longName": "11601 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents", "longName": "11701 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "20302 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "30303 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "btai:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "btai:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables", "longName": "30503 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables", "longName": "30603 - Disclosure - Property and Equipment, Net (Tables)", "shortName": "Property and Equipment, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables", "longName": "30703 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables", "longName": "30803 - Disclosure - Transactions with BioXcel LLC (Tables)", "shortName": "Transactions with BioXcel LLC (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables", "longName": "30903 - Disclosure - Debt and Credit Facilities (Tables)", "shortName": "Debt and Credit Facilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables", "longName": "31203 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureLeasesTables", "longName": "31303 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables", "longName": "31403 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables", "longName": "31503 - Disclosure - Net Loss Per Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails", "longName": "40201 - Disclosure - Basis of Presentation (Details)", "shortName": "Basis of Presentation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_9_30_2023_YaZVjLTSkU6Y_nWVYzVsmg", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true }, "uniqueAnchor": null }, "R36": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "longName": "40301 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment_0UGC9_sYzUelNPSE3BNavg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment_0UGC9_sYzUelNPSE3BNavg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails", "longName": "40401 - Disclosure - Restructuring (Details)", "shortName": "Restructuring (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "Duration_8_8_2023_To_8_8_2023_Od7LoM638E2_O66d9c3Bcg", "name": "btai:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent", "unitRef": "Unit_Standard_pure_3ls9d9S5v0GqU6tjmgM-Dw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_8_8_2023_To_8_8_2023_Od7LoM638E2_O66d9c3Bcg", "name": "btai:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent", "unitRef": "Unit_Standard_pure_3ls9d9S5v0GqU6tjmgM-Dw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails", "longName": "40501 - Disclosure - Inventory (Details)", "shortName": "Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "As_Of_9_30_2023_YaZVjLTSkU6Y_nWVYzVsmg", "name": "us-gaap:InventoryRawMaterials", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_YaZVjLTSkU6Y_nWVYzVsmg", "name": "us-gaap:InventoryRawMaterials", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails", "longName": "40601 - Disclosure - Property and Equipment, Net (Details)", "shortName": "Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_9_30_2023_YaZVjLTSkU6Y_nWVYzVsmg", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_Hwp_5-Ta5EuT-LGhbVCThg", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "unique": true } }, "R40": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails", "longName": "40701 - Disclosure - Accrued Expenses (Details)", "shortName": "Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "As_Of_9_30_2023_YaZVjLTSkU6Y_nWVYzVsmg", "name": "btai:AccruedResearchAndDevelopmentExpenses", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_YaZVjLTSkU6Y_nWVYzVsmg", "name": "btai:AccruedResearchAndDevelopmentExpenses", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails", "longName": "40801 - Disclosure - Transactions with BioXcel LLC (Details)", "shortName": "Transactions with BioXcel LLC (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "As_Of_9_30_2023_YaZVjLTSkU6Y_nWVYzVsmg", "name": "us-gaap:DueToRelatedPartiesCurrent", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_30_2017_To_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_o_ivmV8oNEKLnpS6bKi9DA", "name": "btai:AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "unique": true } }, "R42": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails", "longName": "40901 - Disclosure - Debt and Credit Facilities - Debt summary (Details)", "shortName": "Debt and Credit Facilities - Debt summary (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "As_Of_9_30_2023_YaZVjLTSkU6Y_nWVYzVsmg", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_YaZVjLTSkU6Y_nWVYzVsmg", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails", "longName": "40902 - Disclosure - Debt and Credit Facilities - Credit Agreement (Details)", "shortName": "Debt and Credit Facilities - Credit Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_srt_StatementScenarioAxis_btai_TrancheDMember_AhZDtzCgiE-elPpDl55teQ", "name": "btai:RevenueCovenantNoncompliancePenalty", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_srt_StatementScenarioAxis_btai_TrancheDMember_AhZDtzCgiE-elPpDl55teQ", "name": "btai:RevenueCovenantNoncompliancePenalty", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails", "longName": "40903 - Disclosure - Debt and Credit Facilities - Revenue Interest Financing (Details)", "shortName": "Debt and Credit Facilities - Revenue Interest Financing (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_QTiyej7pvkWriti5d7cm7w", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_MYS5tiH6fE-ANMpG19x3Ew", "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage", "unitRef": "Unit_Standard_pure_3ls9d9S5v0GqU6tjmgM-Dw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "unique": true } }, "R45": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails", "longName": "40904 - Disclosure - Debt and Credit Facilities - Warrants (Details)", "shortName": "Debt and Credit Facilities - Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_b4aO3WVTvEGKdBwyutpBWQ", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Unit_Standard_shares_RppqEyDh80KZAEOgJkGBSA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_b4aO3WVTvEGKdBwyutpBWQ", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Unit_Standard_shares_RppqEyDh80KZAEOgJkGBSA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails", "longName": "40905 - Disclosure - Debt and Credit Facilities - Maturities (Details)", "shortName": "Debt and Credit Facilities - Maturities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As_Of_9_30_2023_YaZVjLTSkU6Y_nWVYzVsmg", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_YaZVjLTSkU6Y_nWVYzVsmg", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails", "longName": "40906 - Disclosure - Debt and Credit Facilities - Interest (Details)", "shortName": "Debt and Credit Facilities - Interest (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_o5fnxzMCYk-cLU56wWtHRQ", "name": "us-gaap:InterestExpenseDebt", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "btai:ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_o5fnxzMCYk-cLU56wWtHRQ", "name": "us-gaap:InterestExpenseDebt", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "btai:ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails", "longName": "41101 - Disclosure - Common Stock Financing Activities (Details)", "shortName": "Common Stock Financing Activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember__y8WrmW_CkiCuXRBOZ0Ssw", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_RppqEyDh80KZAEOgJkGBSA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "btai:FinancingActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "unique": true } }, "R49": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails", "longName": "41201 - Disclosure - Stock-Based Compensation - Description (Details)", "shortName": "Stock-Based Compensation - Description (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_jnTnWEhD9keobaLzADtOmw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "Unit_Standard_shares_RppqEyDh80KZAEOgJkGBSA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_jnTnWEhD9keobaLzADtOmw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "Unit_Standard_shares_RppqEyDh80KZAEOgJkGBSA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails", "longName": "41202 - Disclosure - Stock-Based Compensation - Non-options (Details)", "shortName": "Stock-Based Compensation - Non-options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_o5fnxzMCYk-cLU56wWtHRQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_5_1_2022_To_5_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JsOiWz4q80egPaO-J5RUmw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Unit_Standard_shares_RppqEyDh80KZAEOgJkGBSA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "unique": true } }, "R51": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails", "longName": "41203 - Disclosure - Stock-Based Compensation - Options (Details)", "shortName": "Stock-Based Compensation - Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_RKjDvx5qmkiu1Zw-TWdV5Q", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_RppqEyDh80KZAEOgJkGBSA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_RKjDvx5qmkiu1Zw-TWdV5Q", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_RppqEyDh80KZAEOgJkGBSA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails", "longName": "41204 - Disclosure - Stock-Based Compensation - Assumptions (Details)", "shortName": "Stock-Based Compensation - Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_7H3bhn8Wc0u_DMVS2459oQ", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_7H3bhn8Wc0u_DMVS2459oQ", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails", "longName": "41205 - Disclosure - Stock-Based Compensation - Expense (Details)", "shortName": "Stock-Based Compensation - Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_o5fnxzMCYk-cLU56wWtHRQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_cAmwUjzwUUOlSym1_acCKw", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "unique": true } }, "R54": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails", "longName": "41206 - Disclosure - Stock-Based Compensation - ESPP (Details)", "shortName": "Stock-Based Compensation - ESPP (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_wHKjL6TNukurwacjYnvDJw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "Unit_Standard_shares_RppqEyDh80KZAEOgJkGBSA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_wHKjL6TNukurwacjYnvDJw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "Unit_Standard_shares_RppqEyDh80KZAEOgJkGBSA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails", "longName": "41301 - Disclosure - Leases - Maturities (Details)", "shortName": "Leases - Maturities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "As_Of_9_30_2023_YaZVjLTSkU6Y_nWVYzVsmg", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_YaZVjLTSkU6Y_nWVYzVsmg", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails", "longName": "41302 - Disclosure - Leases - Additional Information (Details)", "shortName": "Leases - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_o5fnxzMCYk-cLU56wWtHRQ", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_o5fnxzMCYk-cLU56wWtHRQ", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails", "longName": "41401 - Disclosure - Fair Value Measurements - Hierarchy (Details)", "shortName": "Fair Value Measurements - Hierarchy (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member__nfGM9o31kmlxOoXmPe8Xw", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member__nfGM9o31kmlxOoXmPe8Xw", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details", "longName": "41402 - Disclosure - Fair Value Measurements - Level 3 (Details)", "shortName": "Fair Value Measurements - Level 3 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "As_Of_12_31_2022_Hwp_5-Ta5EuT-LGhbVCThg", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_Hwp_5-Ta5EuT-LGhbVCThg", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails", "longName": "41403 - Disclosure - Fair Value Measurements - Inputs (Details)", "shortName": "Fair Value Measurements - Inputs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_btai_SeniorSecuredTermLoanMember_m6LW9H0_MEqHHh7beb6Cbw", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_btai_SeniorSecuredTermLoanMember_m6LW9H0_MEqHHh7beb6Cbw", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails", "longName": "41501 - Disclosure - Net Loss Per Share (Details)", "shortName": "Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_o5fnxzMCYk-cLU56wWtHRQ", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "Unit_Standard_shares_RppqEyDh80KZAEOgJkGBSA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "unique": true } }, "R61": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "longName": "41601 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "As_Of_4_30_2022_atvdJHpGPUymz2-37W0HNw", "name": "us-gaap:SignificantSupplyCommitmentRemainingMinimumAmountCommitted", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_4_30_2022_atvdJHpGPUymz2-37W0HNw", "name": "us-gaap:SignificantSupplyCommitmentRemainingMinimumAmountCommitted", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails", "longName": "41701 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lAn2cpn2GUeRTWdR5N06ww", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_IxUiHKGBw0-KWpYkpb2MwQ", "name": "btai:LineOfCreditFacilityInvestmentAllowed", "unitRef": "Unit_Standard_USD__ZcPTIga2EWPXUgMeABesA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "btai-20230930x10q.htm", "unique": true } } }, "tag": { "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r463" ] }, "btai_AdditionalRestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "AdditionalRestrictedCash", "crdr": "debit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "It is additional increase in the minimum maintenance of cash or permitted cash equivalent investments in accounts controlled by OFA for the Lenders.", "label": "Additional Restricted Cash", "terseLabel": "Additional cash to maintained" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails", "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Tranche One", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold improvements", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r55" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options exercised (in dollars per shares)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r319" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected stock price volatility, minimum (as a percent)", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r482" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r465" ] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "InventoryValuationReserves", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory Valuation Reserves", "terseLabel": "Inventory write-downs", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": [ "r53", "r466" ] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureInventory" ], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r229" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r83" ] }, "btai_ShareBasedPaymentArrangementGrantDate2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "ShareBasedPaymentArrangementGrantDate2023Member", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Award granted under share-based payment arrangement during 2023.", "label": "Grant Date 2023" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options granted (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r318" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r131", "r139", "r191", "r227", "r228", "r229", "r404", "r428" ] }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedPaymentArrangementNonemployeeMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Nonemployee consultant", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": [ "r306", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free rate of interest, maximum (as a percent)", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Basis of Presentation" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Basis of Presentation", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r0", "r84" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Tranche Two", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "btai_OnkosxcelTherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "OnkosxcelTherapeuticsMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "OnkosXcel Therapeutics, LLC. refers to the entity's wholly owned subsidiary for its advanced immuno-oncology assets,", "label": "OnkosXcel" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Increase in shares available for issuance (in shares)", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r20", "r130", "r157", "r225", "r249", "r250", "r252", "r253", "r254", "r255", "r256", "r258", "r259", "r351", "r354", "r355", "r371", "r451", "r492", "r534", "r535" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r453" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Work in Process, Gross", "terseLabel": "Work-in-process", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r464" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r161", "r350", "r351", "r354", "r355", "r395", "r420", "r491", "r494", "r495" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit." } } }, "auth_ref": [ "r8", "r68", "r115", "r414", "r415", "r451" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EquipmentMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Equipment", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]" } } }, "auth_ref": [ "r161", "r350", "r351", "r354", "r355", "r395", "r420", "r491", "r494", "r495" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Inventory, Net.", "terseLabel": "Inventory", "totalLabel": "Total inventory", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r140", "r424", "r451" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r28", "r405" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RetainedEarningsMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated Deficit", "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit." } } }, "auth_ref": [ "r127", "r162", "r163", "r164", "r166", "r172", "r174", "r226", "r342", "r343", "r344", "r346", "r347", "r358", "r411", "r413" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SubsequentEventTable", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r378", "r397" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SharePrice", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Share Price", "verboseLabel": "Fair value of grants per share", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r455" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable, Net", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r124", "r125", "r126", "r222", "r223", "r224" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r19" ] }, "us-gaap_PaidInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PaidInKindInterest", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Paid-in-Kind Interest", "terseLabel": "Payable-in-kind interest on Credit Agreement", "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r41" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r56", "r134" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r396", "r398" ] }, "btai_ShareBasedPaymentArrangementGrantDate2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "ShareBasedPaymentArrangementGrantDate2022Member", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Award granted under share-based payment arrangement during 2022.", "label": "Grant Date 2022" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price per Share" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r378", "r397" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Terms of award", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r447" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Stock options", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares outstanding - diluted (in shares)", "verboseLabel": "Weighted average shares (denominator) - diluted (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r177", "r185" ] }, "btai_BorrowingsBasedOnNetSalesPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "BorrowingsBasedOnNetSalesPercent", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the maximum borrowings allowed based on a percentage of net sales.", "label": "Borrowings Based on Net Sales, Percent", "terseLabel": "Borrowing allowed per net sales (as a percent)" } } }, "auth_ref": [] }, "btai_PremiumSharePricePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "PremiumSharePricePercent", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents premium percentage for share price determined over a specified period of time.", "label": "Premium Share Price, Percent", "terseLabel": "Premium share price (as a percent)" } } }, "auth_ref": [] }, "btai_RightToPurchaseStockLenders": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "RightToPurchaseStockLenders", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum equity investment allowed for lenders in entity's common stock.", "label": "Right to Purchase Stock, Lenders", "terseLabel": "Maximum equity investment allowed for lenders" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails", "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Payments for Restructuring", "terseLabel": "Payments for restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r233", "r470" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AwardTypeAxis", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r57", "r118", "r408", "r451" ] }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings", "terseLabel": "Vesting of restricted stock units, net of employee tax obligations", "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r524" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r57", "r417", "r418" ] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r366" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Remaining unamortized expense period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r340" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r456" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "BTI RSU", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares (denominator) - basic (in shares)", "verboseLabel": "Weighted average shares outstanding - basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r176", "r185" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Vesting (as a percent)", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r498" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureLeases" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r388" ] }, "btai_WarrantOaktreeAndQiaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "WarrantOaktreeAndQiaMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to the Oaktree (OFA) Warrants.", "label": "BTI Warrants" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY" } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r158", "r159", "r263", "r292", "r426", "r427" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "verboseLabel": "Total property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r55", "r133" ] }, "btai_EquityInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "EquityInvestmentMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails", "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to the Equity Investment agreement.", "label": "Equity Investment Rights" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentTransitionReport", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r457" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Purchase price as a percent of fair market value", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant-date fair value of options vested (in dollars per share)", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [] }, "btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement", "crdr": "debit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of fees per month to be paid to enter into collaborative service agreement option.", "label": "Additional Fees Per Month to Enter into Collaborative Service Agreement", "terseLabel": "Monthly agreement option fees" } } }, "auth_ref": [] }, "btai_ThresholdRatioOfDebtToRevenueRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "ThresholdRatioOfDebtToRevenueRatio", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents threshold ratio for debt to revenue ratio.", "label": "Threshold Ratio of Debt to Revenue Ratio", "terseLabel": "Debt to revenue multiplier" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r361", "r362", "r367" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r332" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Debt Issuance Costs", "negatedLabel": "Debt issuance costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r36" ] }, "btai_IncentiveAwardPlan2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "IncentiveAwardPlan2020Member", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2020 Incentive Award Plan.", "label": "2020 Incentive Award Plan" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt and Credit Facilities" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Intrinsic value, exercisable", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r78" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "Remainder of 2023", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r533" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Hierarchy [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r274", "r298", "r299", "r300", "r301", "r302", "r303", "r362", "r399", "r400", "r401", "r437", "r438", "r442", "r443", "r444" ] }, "btai_EmployeeStockPurchasePlan2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "EmployeeStockPurchasePlan2020Member", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the 2020 Employee Stock Purchase Plan.", "label": "2020 Employee Stock Purchase Plan" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Type [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r57" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' (deficit) equity" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Type [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r55" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant": { "xbrltype": "percentItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of aggregate number of shares of common stock outstanding of the immediately preceding calendar year as a increase to common stock available for grant under the plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage Of Increase In Common Stock Available For Grant", "terseLabel": "Annual increase in shares available for grant (as a percent)" } } }, "auth_ref": [] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails" ], "lang": { "en-us": { "role": { "label": "Employee Severance [Member]", "terseLabel": "Severance and benefit costs", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred": { "xbrltype": "sharesItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the maximum number of shares issued or transferred under ESPP.", "label": "Employee Stock Purchase Plan, Maximum Number Of Shares Issued Or Transferred", "terseLabel": "Maximum number of shares issued or transferred under ESPP" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property and Equipment, Net" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment, net", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r57" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r385" ] }, "btai_StockPlan2017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "StockPlan2017Member", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to the 2017 Stock Plan.", "label": "2017 Equity Incentive Plan" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual life, exercisable", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r78" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r458" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r524" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "verboseLabel": "Accrued compensation and benefits", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r19" ] }, "btai_FinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "FinancingActivitiesAbstract", "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Common Stock Financing Activities" } } }, "auth_ref": [] }, "btai_SubsidiaryOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "SubsidiaryOwnershipPercentage", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock of subsidiary.", "label": "Subsidiary Ownership, Percentage", "terseLabel": "Subsidiary ownership (as a percent)" } } }, "auth_ref": [] }, "btai_AccruedResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "AccruedResearchAndDevelopmentExpenses", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of accrued research and development expenses.", "label": "Accrued Research And Development Expenses", "terseLabel": "Accrued research and development expenses" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Recurring", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r366", "r368" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted average remaining contractual life, outstanding", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r75" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r93" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r25", "r63", "r127", "r147", "r148", "r149", "r162", "r163", "r164", "r166", "r172", "r174", "r192", "r226", "r294", "r342", "r343", "r344", "r346", "r347", "r358", "r372", "r373", "r374", "r375", "r376", "r377", "r389", "r411", "r412", "r413" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Cancelled in Period", "negatedLabel": "Options cancelled (in shares)" } } }, "auth_ref": [] }, "btai_FinancingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "FinancingActivitiesDisclosureTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for Financing Activities.", "label": "Financing Activities Disclosure [Text Block]", "terseLabel": "Common Stock Financing Activities" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StatementLineItems", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails", "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r274", "r298", "r299", "r300", "r301", "r302", "r303", "r399", "r400", "r401", "r437", "r438", "r442", "r443", "r444" ] }, "btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were cancelled.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Cancelled in Period, Weighted Average Exercise Price", "terseLabel": "Options cancelled (in dollars per shares)" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' (deficit) equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r11", "r107", "r116", "r451", "r474", "r484", "r529" ] }, "btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of Property Plant And Equipment Useful Lives.", "label": "Schedule of Property Plant And Equipment Useful Lives [Table Text Block]", "terseLabel": "Schedule of Property Plant and Equipment useful lives" } } }, "auth_ref": [] }, "btai_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase decrease in operating lease right of use assets.", "label": "Increase Decrease In Operating Lease Right of Use Assets", "negatedLabel": "Operating lease right-of-use assets" } } }, "auth_ref": [] }, "btai_AgreementCommitmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "AgreementCommitmentPeriod", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Period covered by the agreement commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Agreement Commitment, Period", "terseLabel": "Commitment agreement period" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of debt", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r23", "r64", "r65", "r66", "r67", "r97", "r98", "r100", "r111", "r437", "r439", "r476" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r18", "r157", "r225", "r249", "r250", "r252", "r253", "r254", "r255", "r256", "r258", "r259", "r351", "r354", "r355", "r371", "r430", "r492", "r534", "r535" ] }, "btai_CreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "CreditFacilityMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails", "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to financing agreements.", "label": "Credit Facility" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EquityComponentDomain", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r63", "r127", "r147", "r148", "r149", "r162", "r163", "r164", "r166", "r172", "r174", "r192", "r226", "r294", "r342", "r343", "r344", "r346", "r347", "r358", "r372", "r373", "r374", "r375", "r376", "r377", "r389", "r411", "r412", "r413" ] }, "btai_SeniorSecuredTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "SeniorSecuredTermLoanMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails", "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to the Senior Secured Term Loan agreement.", "label": "Credit Agreement and Guaranty", "terseLabel": "Credit Agreement and Guaranty" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StatementTable", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r162", "r163", "r164", "r192", "r405" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r387" ] }, "btai_PaidInKindInterestPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "PaidInKindInterestPercentage", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Paid-in-kind interest rate for funds borrowed, under the debt agreement.", "label": "Paid-in-Kind Interest, Percentage", "terseLabel": "Debt paid-in-kind interest (as a percent)" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EmployeeStockOwnershipPlanESOPDisclosuresLineItems", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" ], "lang": { "en-us": { "role": { "label": "Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]", "terseLabel": "Employee Stock Purchase Plan", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "btai_RevenueInterestFinancingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "RevenueInterestFinancingAgreementMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails", "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to the Revenue Interest Financing agreement", "label": "Revenue interest financing", "terseLabel": "Revenue Interest Financing Agreement" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r454" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts and Other Receivables", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables." } } }, "auth_ref": [ "r40" ] }, "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings", "terseLabel": "Vesting of restricted stock units, net of employee tax obligations (in shares)", "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Schedule of service charges", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "btai_TimeBasedProfitSharingUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "TimeBasedProfitSharingUnitsMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to OnkosXcel time based profit-sharing units", "label": "OnkosXcel PSUs" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Information", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r205", "r206", "r207", "r208", "r209", "r210", "r220" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r454" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r25", "r63", "r68" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r467" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r43", "r132", "r423" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r38", "r96" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital.", "terseLabel": "Additional paid-in-capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r7", "r451" ] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative Assets and Liabilities", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r85", "r86", "r87", "r88", "r89", "r160" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "auth_ref": [] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r361", "r362", "r364", "r365", "r368" ] }, "btai_CreditAgreementThresholdActualRevenueDuringRevenueCovenantMeasurementPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "CreditAgreementThresholdActualRevenueDuringRevenueCovenantMeasurementPeriod", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold actual revenue during the revenue covenant measurement period", "label": "Credit Agreement, Threshold Actual Revenue During Revenue Covenant Measurement Period" } } }, "auth_ref": [] }, "btai_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of positions expected to be eliminated as a percentage of total positions in connection with the restructuring plan(s).", "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated, Percent", "terseLabel": "Expected employees eliminated (as a percent)" } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Common stock equivalents outstanding", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r179", "r180", "r181", "r185", "r309" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails": { "parentTag": "us-gaap_InterestExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "terseLabel": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r31", "r280", "r290", "r439", "r440" ] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Line Items]", "terseLabel": "Debt", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "btai_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long Term Debt Maturities Repayments Of Principal After Year Four", "verboseLabel": "Thereafter" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r454" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r342", "r343", "r344", "r477", "r478", "r479", "r527" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected stock price volatility, maximum (as a percent)", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free rate of interest, minimum (as a percent)", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest income", "negatedLabel": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r30", "r202" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of stock-based compensation charges", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r77" ] }, "btai_PercentageOfValuationApplicableToInitialProfits": { "xbrltype": "percentItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "PercentageOfValuationApplicableToInitialProfits", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of valuation applicable to initial profits.", "label": "Percentage of Valuation Applicable to Initial Profits", "terseLabel": "Percentage of valuation applicable to initial profits" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r158", "r159", "r263", "r292", "r425", "r427" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Options exercised (in shares)", "verboseLabel": "Exercise of stock options (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r5", "r6", "r63", "r68", "r319" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Number of shares issued", "verboseLabel": "Issuance of common shares, net of offering costs (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r5", "r6", "r63", "r68" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Costs and Expenses", "totalLabel": "Total operating expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r27" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of activity relating to RSUs", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r72" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "btai_OrganizationAndPrincipalActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "OrganizationAndPrincipalActivitiesAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Nature of the Business" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Repayments of Debt", "negatedLabel": "Payments", "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations." } } }, "auth_ref": [ "r469" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "FINANCING CASH FLOW ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Net cash used in operating activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r38", "r39", "r42" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Fair value money market accounts", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "btai_CollaborativeArrangementMilestonePaymentsPotential": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "CollaborativeArrangementMilestonePaymentsPotential", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of potential maximum payments that could be paid under the collaborative agreement.", "label": "Collaborative Arrangement, Milestone Payments Potential", "terseLabel": "Potential milestone payments" } } }, "auth_ref": [] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r91", "r95", "r274", "r437", "r438" ] }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedPaymentArrangementEmployeeMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Employee", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": [ "r308", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Options forfeited (in dollars per shares)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r320" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r154" ] }, "btai_BioxcelCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "BioxcelCorporationMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents BioXcel LLC.", "label": "BioXcel LLC" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited, Weighted average price (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r327" ] }, "btai_LesseeOperatingLeaseNumberOfRenewal": { "xbrltype": "integerItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "LesseeOperatingLeaseNumberOfRenewal", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of lessee's options to renew operating lease.", "label": "Lessee Operating Lease Number of Renewal", "terseLabel": "Number of renewal options" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Disclosures of Cash Flow Information", "terseLabel": "Supplemental cash flow information:" } } }, "auth_ref": [] }, "btai_CollaborativeArrangementMilestonePotentialPercent": { "xbrltype": "pureItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "CollaborativeArrangementMilestonePotentialPercent", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the maximum percentage of net sales payable under a collaborative agreement.", "label": "Collaborative Arrangement Milestone Potential Percent", "terseLabel": "Maximum milestone (as as percent)" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair value assets and liabilities", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r154" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r92" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails", "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" ], "lang": { "en-us": { "role": { "label": "Selling, general and administrative", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders' (deficit) equity", "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity." } } }, "auth_ref": [ "r6", "r9", "r10", "r52", "r451", "r474", "r484", "r529" ] }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInInterestPayableNet", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Interest Payable, Net", "terseLabel": "Accrued interest", "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity." } } }, "auth_ref": [ "r40" ] }, "btai_JefferiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "JefferiesMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails", "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Jefferies LLC.", "label": "Jefferies Sale Agreement" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "INVESTING CASH FLOW ACTIVITIES:" } } }, "auth_ref": [] }, "btai_PatentCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "PatentCostsPolicyTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for patent costs.", "label": "Patent Costs [Policy Text Block]", "terseLabel": "Patent Costs" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "OPERATING CASH FLOW ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair value inputs", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r446" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Performance-Based Units, Vested and Expected to Vest [Table Text Block]", "terseLabel": "Schedule of activity relating to PSUs", "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding performance-based awards that are fully vested and expected to vest. Includes, but is not limited to, unvested awards for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r75" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of the period", "periodStartLabel": "Cash and cash equivalents, beginning of the period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r38", "r43", "r45" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 }, "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "totalLabel": "Long-term debt, net", "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r138" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of fair value unobservable inputs", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r92" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options granted (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r318" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedLabel": "Unamortized debt discounts and issuance costs", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r99", "r272", "r288", "r437", "r438" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common shares, net of offering costs", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r5", "r6", "r63", "r68" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r41", "r54" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted average price" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r44" ] }, "btai_SalesMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "SalesMilestonesMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" ], "lang": { "en-us": { "role": { "documentation": "Sales milestones are payable when annual sales reach certain levels.", "label": "Sales milestones" } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r29" ] }, "btai_DevelopmentMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "DevelopmentMilestonesMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" ], "lang": { "en-us": { "role": { "documentation": "Development milestones defined by the collaboration agreement.", "label": "Development milestones" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]", "documentation": "Describes the details pertaining to each employee stock ownership plan." } } }, "auth_ref": [ "r82" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Shares issued under ESPP", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r5", "r6", "r63", "r68" ] }, "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative liability." } } }, "auth_ref": [ "r356" ] }, "btai_DeferredOfferingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "DeferredOfferingCostsPolicyTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferred offering costs.", "label": "Deferred Offering Costs [Policy Text Block]", "terseLabel": "Deferred Initial Public Offering Costs" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2025", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r60", "r161", "r278" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r232", "r233", "r238", "r239" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Scenario, Unspecified [Domain]" } } }, "auth_ref": [ "r175", "r305", "r460", "r480" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Product revenue, net", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r200", "r201", "r211", "r214", "r215", "r219", "r220", "r221", "r295", "r296", "r405" ] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CostOfSalesPolicyTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Cost of Goods Sold", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": [ "r497" ] }, "btai_OfaAdministrativeAgentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "OfaAdministrativeAgentMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents OFA as debt administrative agent.", "label": "OFA" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r112", "r196" ] }, "btai_StepUpDateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "StepUpDateMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "It pertains to date from effective Date until the date on which the second tranche of loans are funded.", "label": "Step Up Date" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r232", "r233", "r234", "r235", "r238", "r239", "r240" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r40" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r102", "r103" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Furniture", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CollaborativeArrangementMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative services agreement", "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity." } } }, "auth_ref": [ "r348" ] }, "btai_LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long Term Debt, Before Unamortized (Discount) Premium and Debt Issuance Costs, Non-Current", "terseLabel": "Long-term debt liability" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Transactions with BioXcel LLC" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureRestructuring" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r231", "r233", "r236", "r241", "r242" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "terseLabel": "Transactions with BioXcel", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation" ], "lang": { "en-us": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r310", "r338", "r339", "r341", "r345", "r446" ] }, "srt_ExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "ExecutiveOfficerMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Executive officers" } } }, "auth_ref": [ "r483" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NatureOfOperations", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureNatureOfBusiness" ], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "terseLabel": "Nature of the Business", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r193", "r199" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r57" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "btai_DebtInstrumentInterestRateDiscountRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "DebtInstrumentInterestRateDiscountRatePercentage", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of basis point original issue discount at which the borrowings under the credit agreement are issued.", "label": "Debt Instrument Interest Rate, Discount Rate Percentage", "terseLabel": "Discount rate (as a percent)" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r454" ] }, "btai_MeasurementInputEstimatedPremiumMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "MeasurementInputEstimatedPremiumMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using estimated premium.", "label": "Estimated premium to 30-day average" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Stock-Based Compensation" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r129", "r142", "r157", "r225", "r249", "r250", "r252", "r253", "r254", "r255", "r256", "r258", "r259", "r350", "r354", "r371", "r451", "r492", "r493", "r534" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstruments" ], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Financial Instruments", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r90", "r357" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "crdr": "debit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Service charges", "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party." } } }, "auth_ref": [ "r101" ] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "GranteeStatusDomain", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Domain]", "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": [ "r306", "r308", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable, accrued expenses, due to related parties, and other current liabilities", "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid." } } }, "auth_ref": [ "r40" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r274", "r298", "r303", "r362", "r399", "r442", "r443", "r444" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Transactions with BioXcel LLC", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r390", "r391", "r392", "r393", "r394" ] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "GranteeStatusAxis", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Axis]", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": [ "r306", "r308", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2024", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r60", "r161", "r278" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings (Loss) Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r47", "r48" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease Liabilities, Payments Due [Abstract]", "terseLabel": "Maturities of the operating lease liability" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails", "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss (numerator)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r26", "r42", "r109", "r121", "r128", "r145", "r146", "r149", "r157", "r165", "r167", "r168", "r169", "r170", "r173", "r174", "r182", "r204", "r212", "r216", "r218", "r225", "r249", "r250", "r252", "r253", "r254", "r255", "r256", "r258", "r259", "r360", "r371", "r431", "r492" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses, other current assets and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r40" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Net Loss Per Share" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "verboseLabel": "Stock-Based Compensation", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "terseLabel": "Outstanding, Weighted average price (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r322", "r323" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r325" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r382" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityShellCompany", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r454" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r327" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Risk-free rate", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r528" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding, ending balance (in shares)", "periodStartLabel": "Outstanding, beginning balance (in shares)", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r322", "r323" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Basic net loss per share attributable to common stockholders (in dollars per share)", "verboseLabel": "Basic net loss per share (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r151", "r167", "r168", "r169", "r170", "r171", "r176", "r178", "r183", "r184", "r185", "r189", "r359", "r360", "r406", "r409", "r429" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "totalLabel": "Total lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r383" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation", "verboseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r40" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Time period", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r528" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r363" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent.", "terseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r128", "r145", "r146", "r153", "r157", "r165", "r173", "r174", "r204", "r212", "r216", "r218", "r225", "r249", "r250", "r252", "r253", "r254", "r255", "r256", "r258", "r259", "r349", "r352", "r353", "r360", "r371", "r407", "r431", "r449", "r450", "r468", "r492" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "UseOfEstimates", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r49", "r50", "r51", "r194", "r195", "r197", "r198" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted, Weighted average price (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r325" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Exercise of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r34", "r79" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Volatility (annual)", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r528" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield (as a percent)", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r334" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r326" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AssetsAbstract", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net loss per share attributable to common stockholders (in dollars per share)", "verboseLabel": "Diluted net loss per share (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r151", "r167", "r168", "r169", "r170", "r171", "r178", "r183", "r184", "r185", "r189", "r359", "r360", "r406", "r409", "r429" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Expense", "terseLabel": "Lease expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r530" ] }, "us-gaap_DueToRelatedPartiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DueToRelatedPartiesCurrent", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Due to Related Parties, Current", "terseLabel": "Due to related parties", "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r15", "r251", "r252", "r253", "r257", "r258", "r259", "r392", "r475" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense.", "terseLabel": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r83", "r123", "r542" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r306", "r308", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Options" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "verboseLabel": "Net Loss Per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r186", "r187", "r188", "r190" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r274", "r370", "r437", "r438" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Available for grant (in shares)", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r78" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Options vested and exercisable (in shares)", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r316" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value, exercised", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r329" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2027", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r60", "r161", "r278" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Derivative Financial Instruments" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r384" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Discount rate", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r528" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options vested and exercisable (in dollars per shares)", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r316" ] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on disposal of equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r41" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Useful life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputExercisePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "MeasurementInputExercisePriceMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Strike price", "documentation": "Measurement input using agreed upon price for exchange of underlying asset." } } }, "auth_ref": [ "r528" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Authorized shares", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r448" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Interest Payable, Current", "terseLabel": "Accrued interest", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected stock price volatility (as a percent)", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r333" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free rate of interest (as a percent)", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r335" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r60", "r161", "r278" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r104", "r114", "r136", "r157", "r204", "r213", "r217", "r225", "r249", "r250", "r252", "r253", "r254", "r255", "r256", "r258", "r259", "r350", "r354", "r371", "r451", "r492", "r493", "r534" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Intrinsic value, outstanding", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r78" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, Net", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r58", "r417", "r418", "r419" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Summary of Significant Accounting Policies", "verboseLabel": "Equipment", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r6", "r63" ] }, "us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition Accounting Policy, Gross and Net Revenue Disclosure [Policy Text Block]", "terseLabel": "Revenue Recognition", "documentation": "Disclosure of accounting policy for recognizing revenue from a transaction on a gross or net basis." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate (as a percent)", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r21", "r98", "r289", "r381" ] }, "us-gaap_DeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DeferredOfferingCosts", "crdr": "debit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Offering Costs.", "terseLabel": "Deferred offering costs", "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period." } } }, "auth_ref": [ "r485" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Valuation Assumptions", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r76" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Option Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r72", "r73", "r74" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt stated interest (as a percent)", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r21", "r261" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails", "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r2", "r3", "r4", "r105", "r106", "r113", "r161", "r260", "r261", "r262", "r263", "r264", "r266", "r272", "r273", "r274", "r275", "r277", "r278", "r279", "r280", "r281", "r282", "r381", "r436", "r437", "r438", "r439", "r440", "r473" ] }, "btai_PercentageOfFairValueConsiderationToBePaid": { "xbrltype": "percentItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "PercentageOfFairValueConsiderationToBePaid", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of fair value of consideration to be paid.", "label": "Percentage of Fair Value Consideration to Be Paid", "terseLabel": "Percentage of fair value of consideration to be paid" } } }, "auth_ref": [] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Taxes Payable, Current", "terseLabel": "Accrued taxes", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r17" ] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "terseLabel": "Option to renew the lease", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": [ "r386" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants to purchase common stock (in shares)", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r293" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails", "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r69", "r70" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value, 100,000 shares authorized as of September 30, 2023 and December 31, 2022; 29,273 and 28,147 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r6", "r451" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r387" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails", "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r23", "r161", "r260", "r261", "r262", "r263", "r264", "r266", "r272", "r273", "r274", "r275", "r277", "r278", "r279", "r280", "r281", "r282", "r381", "r436", "r437", "r438", "r439", "r440", "r473" ] }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": [ "r71" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtInstrumentTable", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r23", "r64", "r65", "r66", "r67", "r97", "r98", "r100", "r111", "r161", "r260", "r261", "r262", "r263", "r264", "r266", "r272", "r273", "r274", "r275", "r277", "r278", "r279", "r280", "r281", "r282", "r285", "r381", "r436", "r437", "r438", "r439", "r440", "r473" ] }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtInstrumentIncreaseAccruedInterest", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Increase, Accrued Interest", "terseLabel": "Accrued interest", "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period." } } }, "auth_ref": [ "r473" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of net loss per share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r481" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "Debt", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of fair value on a recurring basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r361", "r362" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Gross", "terseLabel": "Long-term debt, gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r4", "r106", "r113", "r287" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount borrowed", "verboseLabel": "Revenue Interest Financing Agreement", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r98", "r100", "r260", "r381", "r437", "r438" ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt and Credit Facilities", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r62", "r156", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r276", "r283", "r284", "r286" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Fair value debt", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r274", "r370", "r437", "r438" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventory", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r1", "r12", "r13", "r14" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Common stock issuable (in shares)", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "verboseLabel": "Other accrued expenses", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r293" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r6" ] }, "us-gaap_DebtInstrumentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtInstrumentFeeAmount", "crdr": "debit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Fee Amount", "terseLabel": "Debt instrument fee", "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of maturities on long-term debt", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r60" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of changes in Level 3 liabilities", "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r93", "r94" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails" ], "lang": { "en-us": { "role": { "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r232", "r233", "r238", "r239" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "negatedTerseLabel": "Offering costs for common stock issuance", "verboseLabel": "Stock offering costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r37" ] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "StatementScenarioAxis", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r175", "r305", "r460", "r461", "r480" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, ending balance (in shares)", "periodStartLabel": "Outstanding, beginning balance (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r314", "r315" ] }, "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtCurrent", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Debt, Current", "negatedLabel": "Debt classified as current", "documentation": "Amount of debt and lease obligation, classified as current." } } }, "auth_ref": [ "r137" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested aggregate (in shares)", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r330" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2023", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r476" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Payment of employee tax obligations related to vesting restricted stock units", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r152" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 3.0 }, "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest Expense", "terseLabel": "Interest expense", "totalLabel": "Total interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r99", "r110", "r150", "r203", "r379" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r459" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, end balance (in dollars per shares)", "periodStartLabel": "Outstanding, beginning balance (in dollars per shares)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r314", "r315" ] }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DerivativeLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Derivative Liability, Noncurrent", "terseLabel": "Derivative liabilities", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r143" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair value of non-options granted (in dollars per share)", "verboseLabel": "Weighted-average grant-date fair value of options granted (in dollars per share)", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r328" ] }, "us-gaap_DerivativeLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DerivativeLiabilityMeasurementInput", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Liability, Measurement Input", "terseLabel": "Derivative liability input", "documentation": "Value of input used to measure derivative liability." } } }, "auth_ref": [ "r365" ] }, "us-gaap_DebtPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtPolicyTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Debt, Policy [Policy Text Block]", "terseLabel": "Debt and Detachable Warrants", "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }, "auth_ref": [ "r60" ] }, "us-gaap_ContractTerminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ContractTerminationMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails" ], "lang": { "en-us": { "role": { "label": "Contract Termination [Member]", "terseLabel": "Contract termination costs", "documentation": "Termination of a contract associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [ "r432", "r433", "r434", "r435" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Options forfeited (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r320" ] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued Expenses", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r19" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Issuance of stock purchase warrants", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r61", "r63", "r68" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of equipment and leasehold improvements", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts receivable, net", "terseLabel": "Accounts receivable, net", "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value." } } }, "auth_ref": [ "r117", "r122", "r451" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails", "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r230", "r234" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "verboseLabel": "Number of Shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AwardDateAxis", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Reconciliation of net loss to net cash (used in) provided by operating activities:", "verboseLabel": "Reconciliation of net loss to net cash used in operating activities" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested, Weighted average price (in dollars per share)", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r330" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r19", "r451" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r525" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r369" ] }, "us-gaap_LiabilitiesFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesFairValueAdjustment", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details" ], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Adjustment", "terseLabel": "Change in fair value", "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "MaximumMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Maximum" } } }, "auth_ref": [ "r245", "r246", "r247", "r248", "r304", "r403", "r410", "r421", "r422", "r441", "r445", "r452", "r496", "r536", "r537", "r538", "r539", "r540", "r541" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Equity Award [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other expense (income), net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r32" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "MinimumMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Minimum" } } }, "auth_ref": [ "r245", "r246", "r247", "r248", "r304", "r403", "r410", "r421", "r422", "r441", "r445", "r452", "r496", "r536", "r537", "r538", "r539", "r540", "r541" ] }, "us-gaap_InterestExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "InterestExpenseAbstract", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest Expense [Abstract]", "terseLabel": "Other expense (income)" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r80", "r81", "r307" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "RangeAxis", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "auth_ref": [ "r245", "r246", "r247", "r248", "r297", "r304", "r333", "r334", "r335", "r402", "r403", "r410", "r421", "r422", "r441", "r445", "r452", "r486", "r496", "r537", "r538", "r539", "r540", "r541" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "RangeMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Range [Domain]" } } }, "auth_ref": [ "r245", "r246", "r247", "r248", "r297", "r304", "r333", "r334", "r335", "r402", "r403", "r410", "r421", "r422", "r441", "r445", "r452", "r486", "r496", "r537", "r538", "r539", "r540", "r541" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails", "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r234" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "negatedLabel": "Less current portion of lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r383" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term portion of operating lease liabilities", "verboseLabel": "Long-term portion operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r383" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AwardDateDomain", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Award Date [Domain]", "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r5", "r291" ] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails": { "parentTag": "us-gaap_InterestExpense", "weight": 1.0, "order": 2.0 }, "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Accretion of debt discount and amortization of financing costs", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r282", "r380", "r439", "r440", "r472" ] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r471", "r532" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r5", "r291" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SubsequentEventMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r378", "r397" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails", "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r34" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r378", "r397" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r274", "r298", "r299", "r300", "r301", "r302", "r303", "r362", "r401", "r437", "r438", "r442", "r443", "r444" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Liability", "terseLabel": "Derivative liabilities", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r143", "r144", "r370", "r427" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails", "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails", "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Restructuring Charges", "terseLabel": "Restructuring costs", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r41", "r237", "r238", "r487" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Events", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "verboseLabel": "Renewal term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r531" ] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Table]", "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r16", "r473" ] }, "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "WarrantsNotSettleableInCashFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants Not Settleable in Cash, Fair Value Disclosure", "terseLabel": "Fair value warrant classified as equity", "documentation": "Fair value portion of warrants not settleable in cash classified as equity." } } }, "auth_ref": [ "r91" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r46", "r155" ] }, "btai_RestrictedStockUnitsOnkosxcelMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "RestrictedStockUnitsOnkosxcelMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "documentation": "Share instrument associated with OnkosXcel, which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "OnkosXcel RSUs" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r387" ] }, "btai_PercentageOfOutstandingLoan": { "xbrltype": "percentItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "PercentageOfOutstandingLoan", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of outstanding Loan.", "label": "Percentage of Outstanding Loan", "terseLabel": "Outstanding loan (as a percent)" } } }, "auth_ref": [] }, "us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SignificantSupplyCommitmentRemainingMinimumAmountCommitted", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Supply Commitment, Remaining Minimum Amount Committed", "terseLabel": "Minimum annual payments", "documentation": "The floor amount as of the balance sheet date that the entity must expend to satisfy the terms of disclosed arrangements (excluding long-term commitments) in which the entity must commit resources to supply goods or services to one or more customers." } } }, "auth_ref": [ "r24", "r108", "r119" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r5" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r387" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies.", "terseLabel": "Commitments and contingencies (Note 16)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r24", "r108", "r120" ] }, "btai_LineOfCreditFacilityExitFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "LineOfCreditFacilityExitFeePercentage", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "The line of credit facility exit fee, expressed as a percentage.", "label": "Line of Credit Facility, Exit Fee Percentage", "terseLabel": "Exit fee (as a percent)" } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Level 3 liabilities reconciliation", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Computers and equipment", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r15", "r451" ] }, "btai_MeasurementInputProbabilityOfExerciseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "MeasurementInputProbabilityOfExerciseMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which there is a probability of exercise.", "label": "Probability of exercise" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r204", "r212", "r216", "r218", "r431" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r59", "r243", "r244", "r416", "r490" ] }, "btai_ThresholdRatioOfDebtToPurchasersInvestedCapitalRatioYearOne": { "xbrltype": "pureItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "ThresholdRatioOfDebtToPurchasersInvestedCapitalRatioYearOne", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt to purchasers invested capital multiplier in next twelve months.", "label": "Threshold Ratio of Debt to Purchasers Invested Capital Ratio, Year One", "terseLabel": "Purchasers invested capital multiplier in year one" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r387" ] }, "btai_AfterStepUpDateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "AfterStepUpDateMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "It pertains to date from and after the Step-Up Date.", "label": "After Step Up Date" } } }, "auth_ref": [] }, "btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest expense associated with long-term debt.", "label": "Schedule of Interest Expense Associated with Long Term Debt [Table Text Block]", "terseLabel": "Schedule of long-term debt interest expense" } } }, "auth_ref": [] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value, 10,000 shares authorized; no shares issued and outstanding as of September 30, 2023 and December 31, 2022", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r5", "r451" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "auth_ref": [] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PlanNameDomain", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523" ] }, "btai_TrancheBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "TrancheBMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Tranche B.", "label": "Tranche B" } } }, "auth_ref": [] }, "btai_ThresholdRatioOfDebtToPurchasersInvestedCapitalRatioYearTwo": { "xbrltype": "pureItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "ThresholdRatioOfDebtToPurchasersInvestedCapitalRatioYearTwo", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt to purchasers invested capital multiplier in two years.", "label": "Threshold Ratio of Debt to Purchasers Invested Capital Ratio, Year Two", "verboseLabel": "Purchasers invested capital multiplier in year two" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Commitment fee (as a percent)", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "btai_ThresholdRatioOfDebtToPurchasersInvestedCapitalRatioYearThree": { "xbrltype": "pureItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "ThresholdRatioOfDebtToPurchasersInvestedCapitalRatioYearThree", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt to purchasers invested capital multiplier in three years.", "label": "Threshold Ratio of Debt to Purchasers Invested Capital Ratio, Year Three", "verboseLabel": "Purchasers invested capital multiplier in year three" } } }, "auth_ref": [] }, "btai_NetCashRequiredMinimum": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "NetCashRequiredMinimum", "crdr": "debit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Minimum maintenance of cash or permitted cash equivalent investments in accounts controlled by lenders.", "label": "Net Cash Required, Minimum", "terseLabel": "Cash maintenance in controlled accounts" } } }, "auth_ref": [] }, "btai_ThresholdRatioOfDebtToPurchasersInvestedCapitalRatioYearFourAndThereafter": { "xbrltype": "pureItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "ThresholdRatioOfDebtToPurchasersInvestedCapitalRatioYearFourAndThereafter", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt to purchasers invested capital multiplier in four years and thereafter.", "label": "Threshold Ratio of Debt to Purchasers Invested Capital Ratio, Year Four and Thereafter", "terseLabel": "Purchasers invested capital multiplier in four years and thereafter" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PlanNameAxis", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523" ] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value of Derivative Liabilities", "negatedLabel": "Change in fair value of derivative liabilities", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r526" ] }, "btai_TrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "TrancheMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Tranche A.", "label": "Tranche A" } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "VestingAxis", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523" ] }, "btai_TrancheCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "TrancheCMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Tranche C.", "label": "Tranche C" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails", "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Allocated Share-based Compensation Expense", "terseLabel": "Share-based compensation costs recognized", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r337" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r16" ] }, "btai_OnkosxcelWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "OnkosxcelWarrantMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails", "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails", "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to OnkosXcel.", "label": "OnkosXcel Warrants" } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntitySmallBusiness", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r454" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommonStockMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Common stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r477", "r478", "r527" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "VestingDomain", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails", "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r5" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r135" ] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails", "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Remaining borrowing capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Proceeds from long-term debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r35" ] }, "btai_ThresholdLiquidityEventAmountForExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "ThresholdLiquidityEventAmountForExerciseOfWarrants", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold amount of liquidity event for exercise of warrants.", "label": "Threshold Liquidity Event Amount for Exercise of Warrants", "terseLabel": "Threshold amount of liquidity event for exercise of warrants" } } }, "auth_ref": [] }, "btai_AggregatePrepaymentFeeMaximum": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "AggregatePrepaymentFeeMaximum", "crdr": "debit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents maximum aggregate prepayment fee.", "label": "Aggregate Prepayment Fee, Maximum", "terseLabel": "Aggregate Prepayment Fee" } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFilerCategory", "presentation": [ "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r454" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Summary of maturities of the operating lease liability", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r533" ] }, "btai_RevenueCovenantNoncompliancePenalty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "RevenueCovenantNoncompliancePenalty", "crdr": "debit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum payment required per debt agreement if failure to satisfy the Revenue Covenant.", "label": "Revenue Covenant Noncompliance Penalty", "terseLabel": "Revenue covenant noncompliance payment" } } }, "auth_ref": [] }, "btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a cancelled event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Cancelled, Weighted Average Grant Date Fair Value", "terseLabel": "Cancelled, Weighted average price (in dollars per share)" } } }, "auth_ref": [] }, "btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Cancelled in Period", "negatedLabel": "Cancelled (in shares)" } } }, "auth_ref": [] }, "btai_TrancheBAndTrancheCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "TrancheBAndTrancheCMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Tranche B and Trance C", "label": "Tranche B and C" } } }, "auth_ref": [] }, "us-gaap_RestructuringReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RestructuringReserveCurrent", "crdr": "credit", "calculation": { "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails", "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Reserve, Current", "terseLabel": "Accrued restructuring costs", "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset." } } }, "auth_ref": [ "r462", "r488", "r489" ] }, "btai_TrancheDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "TrancheDMember", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Tranche D.", "label": "Tranche D [Member]", "terseLabel": "Tranche D" } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SubsidiarySaleOfStockLineItems", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Shares issued", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "btai_LineOfCreditFacilityAmendmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "LineOfCreditFacilityAmendmentFeePercentage", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "The line of credit facility fee for credit agreement amendment based on a loans outstanding, expressed as a percentage.", "label": "Line of Credit Facility, Amendment Fee Percentage", "terseLabel": "Amendment fee (as a percent)" } } }, "auth_ref": [] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "documentation": "Different names of stock transactions and the different attributes of each transaction." } } }, "auth_ref": [] }, "btai_LineOfCreditFacilityInvestmentAllowed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioxceltherapeutics.com/20230930", "localname": "LineOfCreditFacilityInvestmentAllowed", "crdr": "credit", "presentation": [ "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum amount the Lenders agree to permit the entity to invest in subsidiary.", "label": "Line of Credit Facility, Investment Allowed", "terseLabel": "Maximum investment allowed" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets, Current", "terseLabel": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r141", "r451" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(b))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "24", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "28", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "8", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "330", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.BB)", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "6", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "7", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "50", "Section": "S99", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(b),(f(1))", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "40", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "730", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "URI": "https://asc.fasb.org/topic&trid=2229140" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "230", "Section": "45", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(16))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03.(a)(19))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03.(a),19)", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "946", "SubTopic": "210", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-06(3))", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "6", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "105", "SubTopic": "10", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "7", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "5", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "20", "Section": "55", "Paragraph": "10", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "50", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "50", "Paragraph": "5", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "50", "Paragraph": "6", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "24", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "45", "Paragraph": "24", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "8", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "9", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "10", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "16", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "22", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "28A", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "7", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "15", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "270", "SubTopic": "10", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "272", "SubTopic": "10", "Section": "45", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "11", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "12", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "29", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "42", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "20", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "323", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "326", "SubTopic": "10", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "330", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "330", "SubTopic": "10", "Section": "50", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(e))", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "420", "URI": "https://asc.fasb.org/topic&trid=2175745" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "440", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "440", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "450", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "450", "SubTopic": "20", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "450", "SubTopic": "20", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "450", "SubTopic": "20", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "50", "Paragraph": "5", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "80", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "80", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "35", "Paragraph": "1D", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "35", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "35", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "45", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "808", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "19", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "6A", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "10", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "45", "Paragraph": "17", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "45", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "50", "Paragraph": "6", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "848", "SubTopic": "10", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "6", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "852", "SubTopic": "10", "Section": "45", "Paragraph": "14", "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "855", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "855", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "910", "SubTopic": "10", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "912", "SubTopic": "330", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "924", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "235", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "360", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "954", "SubTopic": "440", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "958", "SubTopic": "360", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "958", "SubTopic": "360", "Section": "50", "Paragraph": "6", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "958", "SubTopic": "360", "Section": "50", "Paragraph": "7", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "970", "SubTopic": "360", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "976", "SubTopic": "310", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "978", "SubTopic": "310", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r423": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r424": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r425": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "20", "Section": "55", "Paragraph": "16", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r426": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "20", "Section": "55", "Paragraph": "21", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r427": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "20", "Section": "55", "Paragraph": "22", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r428": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r429": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r430": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r431": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r432": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r433": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r434": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r435": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r436": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r437": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "55", "Paragraph": "69B", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r438": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "55", "Paragraph": "69C", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r439": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "55", "Paragraph": "69E", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r440": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "55", "Paragraph": "69F", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r441": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r442": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r443": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r444": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r445": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "80", "Section": "55", "Paragraph": "8", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r446": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r447": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r448": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r449": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r450": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r451": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "852", "SubTopic": "10", "Section": "55", "Paragraph": "10", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r452": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "55", "Paragraph": "29F", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r453": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r454": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r457": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r459": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r460": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "450", "SubTopic": "20", "Section": "50", "Paragraph": "10", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r461": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "855", "SubTopic": "10", "Section": "50", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r462": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r463": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r464": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r465": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r466": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r467": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r468": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "50", "Paragraph": "6", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r469": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r470": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r471": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r472": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r473": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r474": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r475": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r476": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r477": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r478": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "45", "Paragraph": "24", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r479": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r480": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r481": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r482": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "18", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r483": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "45", "Paragraph": "13", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r484": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "323", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r485": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "340", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.A)", "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735" }, "r486": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "410", "SubTopic": "30", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r487": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "45", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868" }, "r488": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r489": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r490": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r491": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r492": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r493": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r496": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r497": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "705", "URI": "https://asc.fasb.org/topic&trid=2122478" }, "r498": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r499": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r500": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r501": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r502": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r503": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r504": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r505": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r506": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r507": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r508": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r509": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r510": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r511": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r512": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r513": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "808", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "50", "Paragraph": "6", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "852", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "852", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "912", "SubTopic": "730", "Section": "25", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" } } }